ArticleCancer medicine2025
Prognostic Factors in Patients With Locally Advanced Hypopharyngeal Squamous Cell Carcinoma After Radical Radiotherapy/Chemoradiotherapy.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prediction of Residual Disease in Unresectable Head and Neck Squamous Cell Carcinoma After Concurrent Chemoradiotherapy.World journal of oncology · 2026Article
- Prognostic Factors in Patients With Locally Advanced Hypopharyngeal Squamous Cell Carcinoma After Radical Radiotherapy/Chemoradiotherapy.Cancer medicine · 2025Article
- Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo analyze treatment efficacy and prognostic factors in patients with locally advanced hypopharyngeal squamous cell carcinoma (LA-HPSCC) treated with radical radiotherapy (RT)/chemoradiotherapy (CRT).
methodsWe retrospectively enrolled LA-HPSCC patients treated with radical RT or CRT during 2015-2021. Clinical and inflammatory factors affecting treatment efficacy were analyzed using SPSS (v27).
resultsIn all, 193 patients (179 male and 14 female patients) were enrolled. The 1-year, 3-year, and median overall survival (OS) were 78.2%, 41.1%, and 28.9 months, respectively. The 1-year, 3-year, and median progression-free survival (PFS) were 69.9%, 34.7%, and 21.8 months, respectively. Univariate analysis showed that second primary cancer, albumin-fibrinogen ratio (AFR), platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), clinical T (cT) stage, TNM stage, treatment modality, and short-term treatment response were associated with OS (p < 0.05), while AFR, PLR, cT stage, treatment modality, and short-term response were associated with PFS (p < 0.05). Multivariate analysis revealed AFR and short-term response as independent risk factors for OS and PFS, and cT and second primary cancer as independent risk factors for OS. Compared with those not receiving concurrent chemoradiotherapy (CCRT), those treated with CCRT had improved OS and PFS if they were aged ≥ 70 years, or had N2/N3 or stage III/IVA disease (p < 0.05).
conclusionsOS and PFS were higher in patients with early cTNM, high AFR, low PLR, CCRT, and good short-term response. Patients with low NLR had higher OS and a higher incidence of second primary cancers (commonly esophageal and lung cancers).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.